IMPAACT 1077HS (VS 10) HAART STANDARD VERSION OF THE PROMISE STUDY

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 过去二十年来，在预防艾滋病毒母婴传播方面取得了长足进展。在美国，妊娠期间给予病毒学抑制性抗逆转录病毒药物组合（通常称为高效抗逆转录病毒疗法（HAART））、剖宫产分娩和婴儿配方奶粉喂养（FF）已导致母婴传播风险降低至2%以下，并实际消除了新发儿科HIV感染，欧洲和其他资源丰富的地区。剩下的问题基本上围绕着改善服务的提供，特别是在怀孕前和怀孕期间及早发现所有感染艾滋病毒的妇女，以便提供适当的咨询和适当的抗逆转录病毒疗法。确定停止HAART的安全性时，仅用于预防母婴传播仍然是一个重要的悬而未决的问题。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Over the past two decades, considerable strides have been made in the prevention of mother-to-child transmission (PMTCT) of HIV. The administration during pregnancy of virologically suppressive antiretroviral drug combinations conventionally referred to as highly-active anti retroviral therapies (HAART), cesarean section delivery, and infant formula-feeding (FF) have led to a decrease of the risk of MTCT to less than 2% and the virtual elimination of new pediatric HIV infection in the U.S., Europe, and other resource-advantaged settings. Remaining issues essentially revolve around improved service delivery, in particular the detection of all HIV-infected women prior to conception and early enough during pregnancy so that appropriate counseling and appropriate ART can be provided. Determining the safety of stopping HAART when used solely for prophylaxis of MTCT remains an important unresolved issue.